Warburg Research analyst Ulrich Huwald maintained a Hold rating on Qiagen (NYSE:QGEN) NV on Wednesday, setting a price target of EUR46.2, which is approximately 11.13% above the present share price of $50.35.
Huwald expects Qiagen NV to post earnings per share (EPS) of $0.07 for the fourth quarter of 2020.
The current consensus among 9 TipRanks analysts is for a Moderate Buy rating of shares in Qiagen, with an average price target of $57.46.
The analysts price targets range from a high of $62.98 to a low of $44.81.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $483.76 million and a net profit of $149.31 million. The company's market cap is $11.04 billion.
According to TipRanks.com, Warburg Research analyst Ulrich Huwald is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -5.6% and a 31.03% success rate.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.